Gemcitabine-based regimen for primary ovarian angiosarcoma with MYC amplification

I. Yonezawa, M. Waki, Y. Tamura, R. Onoda, M. Narushima, T. Ishizuka, S. Tajima

Abstract


Angiosarcoma is a rare and aggressive type of sarcoma, and primary angiosarcoma of the ovary is extremely rare. We report the case of a 29-year-old woman who was diagnosed with ovarian angiosarcoma and possible bone metastases. We treated this patient with a gemcitabine-based regimen as postoperative adjuvant chemotherapy, after which she achieved at least 7 years of progression-free survival, an extremely long duration given the aggressive features of this tumour. We retrospectively performed immunohistochemical analyses and fluorescence in situ hybridization to make a pathology diagnosis and to investigate the tumour features. MYC amplification and c-Myc protein overexpression were positively detected. It might be possible to correlate the effectiveness of the gemcitabine-based chemotherapeutic regimen with MYC gene amplification and c-Myc protein overexpression.

Keywords


angiosarcoma; mucinous cystadenoma; surgical resection; chemotherapy; gemcitabine; MYC

Full Text:

PDF HTML


DOI: http://dx.doi.org/10.3747/co.21.2144






Copyright © 2019 Multimed Inc.
ISSN: 1198-0052 (Print) ISSN: 1718-7729 (Online)